AP 1100

Drug Profile

AP 1100

Alternative Names: AP-1100

Latest Information Update: 23 Sep 2011

Price : $50

At a glance

  • Originator Ariel Pharmaceuticals
  • Class Cytoprotectives; Neuroprotectants
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Phase I Haemorrhagic shock

Most Recent Events

  • 23 Sep 2011 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top